Drug Coverage

The first generic equivalent of the HIV therapeutic is now available.

The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.

The review will determine whether there should be a national Medicare coverage policy for the Alzheimer’s therapy.

Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.

The specialty pharmacy is licensed in all 50 states.

Orally dissolving film formulation of riluzole is now available for patients who have difficulty swallowing.

The prescribing information for Aduhelm now specifies its use in patients with a mild form of the disease.

Coverage now includes 85% of commercial lives.

Formulary adoption is a key step in achieving sales pull through starting in 2022, company officials said.

Patients are being offered $500 to make the switch.

A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.

Implementation of value-based approaches requires measurement of value, authors said.

Investigators looked at the association of antiparasitic drug prices with prescribing and prescription-filling behaviors and total outpatient treatment costs.

A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.

Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.

Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.

The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.

Three commercial plans now cover the corticosteroid Eysuvis.